188 related articles for article (PubMed ID: 24147068)
1. Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.
Wei JS; Johansson P; Chen L; Song YK; Tolman C; Li S; Hurd L; Patidar R; Wen X; Badgett TC; Cheuk AT; Marshall JC; Steeg PS; Vaqué Díez JP; Yu Y; Gutkind JS; Khan J
PLoS One; 2013; 8(10):e77731. PubMed ID: 24147068
[TBL] [Abstract][Full Text] [Related]
2. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
[TBL] [Abstract][Full Text] [Related]
3. Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
Cheung NK; Zhang J; Lu C; Parker M; Bahrami A; Tickoo SK; Heguy A; Pappo AS; Federico S; Dalton J; Cheung IY; Ding L; Fulton R; Wang J; Chen X; Becksfort J; Wu J; Billups CA; Ellison D; Mardis ER; Wilson RK; Downing JR; Dyer MA;
JAMA; 2012 Mar; 307(10):1062-71. PubMed ID: 22416102
[TBL] [Abstract][Full Text] [Related]
4. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
5. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.
Molenaar JJ; Koster J; Zwijnenburg DA; van Sluis P; Valentijn LJ; van der Ploeg I; Hamdi M; van Nes J; Westerman BA; van Arkel J; Ebus ME; Haneveld F; Lakeman A; Schild L; Molenaar P; Stroeken P; van Noesel MM; Ora I; Santo EE; Caron HN; Westerhout EM; Versteeg R
Nature; 2012 Feb; 483(7391):589-93. PubMed ID: 22367537
[TBL] [Abstract][Full Text] [Related]
6. Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells.
Hayashi M; Okabe K; Kato K; Okumura M; Fukui R; Fukushima N; Tsujiuchi T
Cancer Lett; 2012 Mar; 316(1):91-6. PubMed ID: 22079467
[TBL] [Abstract][Full Text] [Related]
7. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
[TBL] [Abstract][Full Text] [Related]
8. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
9. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
[TBL] [Abstract][Full Text] [Related]
10. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
11. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Sausen M; Leary RJ; Jones S; Wu J; Reynolds CP; Liu X; Blackford A; Parmigiani G; Diaz LA; Papadopoulos N; Vogelstein B; Kinzler KW; Velculescu VE; Hogarty MD
Nat Genet; 2013 Jan; 45(1):12-7. PubMed ID: 23202128
[TBL] [Abstract][Full Text] [Related]
12. RNA-Sequencing Combined With Genome-Wide Allele-Specific Expression Patterning Identifies ZNF44 Variants as a Potential New Driver Gene for Pediatric Neuroblastoma.
Sun L; Li X; Tu L; Stucky A; Huang C; Chen X; Cai J; Li SC
Cancer Control; 2023; 30():10732748231175017. PubMed ID: 37161925
[TBL] [Abstract][Full Text] [Related]
13. The genetic landscape of high-risk neuroblastoma.
Pugh TJ; Morozova O; Attiyeh EF; Asgharzadeh S; Wei JS; Auclair D; Carter SL; Cibulskis K; Hanna M; Kiezun A; Kim J; Lawrence MS; Lichenstein L; McKenna A; Pedamallu CS; Ramos AH; Shefler E; Sivachenko A; Sougnez C; Stewart C; Ally A; Birol I; Chiu R; Corbett RD; Hirst M; Jackman SD; Kamoh B; Khodabakshi AH; Krzywinski M; Lo A; Moore RA; Mungall KL; Qian J; Tam A; Thiessen N; Zhao Y; Cole KA; Diamond M; Diskin SJ; Mosse YP; Wood AC; Ji L; Sposto R; Badgett T; London WB; Moyer Y; Gastier-Foster JM; Smith MA; Guidry Auvil JM; Gerhard DS; Hogarty MD; Jones SJ; Lander ES; Gabriel SB; Getz G; Seeger RC; Khan J; Marra MA; Meyerson M; Maris JM
Nat Genet; 2013 Mar; 45(3):279-84. PubMed ID: 23334666
[TBL] [Abstract][Full Text] [Related]
14. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Shukla N; Ameur N; Yilmaz I; Nafa K; Lau CY; Marchetti A; Borsu L; Barr FG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(3):748-57. PubMed ID: 22142829
[TBL] [Abstract][Full Text] [Related]
15. A system for detecting high impact-low frequency mutations in primary tumors and metastases.
Anjanappa M; Hao Y; Simpson ER; Bhat-Nakshatri P; Nelson JB; Tersey SA; Mirmira RG; Cohen-Gadol AA; Saadatzadeh MR; Li L; Fang F; Nephew KP; Miller KD; Liu Y; Nakshatri H
Oncogene; 2018 Jan; 37(2):185-196. PubMed ID: 28892047
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of ATRX or DAXX mutated neuroblastoma.
Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry for ATRX Can Miss ATRX Mutations: Lessons From Neuroblastoma.
Chami R; Marrano P; Teerapakpinyo C; Arnoldo A; Shago M; Shuangshoti S; Thorner PS
Am J Surg Pathol; 2019 Sep; 43(9):1203-1211. PubMed ID: 31290759
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression.
Rifatbegovic F; Frech C; Abbasi MR; Taschner-Mandl S; Weiss T; Schmidt WM; Schmidt I; Ladenstein R; Ambros IM; Ambros PF
Int J Cancer; 2018 Jan; 142(2):297-307. PubMed ID: 28921546
[TBL] [Abstract][Full Text] [Related]
19. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.
Martinsson T; Eriksson T; Abrahamsson J; Caren H; Hansson M; Kogner P; Kamaraj S; Schönherr C; Weinmar J; Ruuth K; Palmer RH; Hallberg B
Cancer Res; 2011 Jan; 71(1):98-105. PubMed ID: 21059859
[TBL] [Abstract][Full Text] [Related]
20. Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas.
Cutcutache I; Suzuki Y; Tan IB; Ramgopal S; Zhang S; Ramnarayanan K; Gan A; Lee HH; Tay ST; Ooi A; Ong CK; Bolthouse JT; Lane BR; Anema JG; Kahnoski RJ; Tan P; Teh BT; Rozen SG
Eur Urol; 2015 Jul; 68(1):77-83. PubMed ID: 25597018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
